Tharimmune Company Insiders

Tharimmune Management Team Effectiveness

The company has return on total asset (ROA) of (0.9979) % which means that it has lost $0.9979 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2501) %, meaning that it created substantial loss on money invested by shareholders. Tharimmune's management efficiency ratios could be used to measure how well Tharimmune manages its routine affairs as well as how well it operates its assets and liabilities. As of 01/15/2026, Return On Tangible Assets is likely to drop to -3.1. In addition to that, Return On Capital Employed is likely to grow to -10.39. At this time, Tharimmune's Net Tangible Assets are relatively stable compared to the past year. As of 01/15/2026, Other Current Assets is likely to grow to about 196.9 K, while Total Assets are likely to drop slightly above 4.1 M. As of 01/15/2026, Common Stock Shares Outstanding is likely to grow to about 1.6 M, though Net Loss is likely to grow to (7.2 M). Tharimmune shows a total of 37.39 Million outstanding shares. Tharimmune has 7.34 % of its outstanding shares held by insiders and 3.19 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Tharimmune in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Tharimmune, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Tharimmune Workforce Comparison

Tharimmune Insider Trading

Tharimmune Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Tharimmune often depends on how effective the management is. Tharimmune management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tharimmune management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tharimmune management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.